INDUSTRY ESSENTIALS

Enhancing AD care: Consensus statements for biomarker and AAT options

19 Oct 2026

Hong Kong Medical Journal 2026

Shum CK, Shea YF, Au Yeung TW, Chan CYC, Chan WC, Cheng WK, Cheung YFN, Cho HYD, TK Chow, Fong CYG, Ip BYM, Kwok SHJ, Lai MHB, Lam CWL, Lee TCA, Lok CM, Mok KY, Ng KKD, Siu YWD, Yeung PY, Tam KFS. Consensus statement on the use of Alzheimer’s disease biomarkers and anti-amyloid therapies in Hong Kong. Hong Kong Med J 2026;32:144-54.

Alzheimer’s disease (AD) is the leading cause of cognitive impairment in Hong Kong and globally.1 The advent of anti-amyloid therapies (AATs) and advanced biomarkers marks a critical paradigm shift in disease management.1 To provide local guidance, a multidisciplinary panel of medical specialists including geriatricians, psychiatrists, neurologists, nuclear medicine physicians, and radiologists has developed 26 consensus recommendations tailored for the Hong Kong healthcare setting.1 This guidance addresses the clinical application of AD biomarkers (table 1) and the safe implementation of AATs (table 2), providing a vital framework to optimize diagnostic accuracy and therapeutic outcomes across the region.1

The diagnostic accuracy of AD remains suboptimal at 61% in primary care.1 The consensus emphasizes that biomarker testing should be reserved exclusively for individuals demonstrating clinically relevant cognitive impairment.1 Crucially, biomarker confirmation of AD pathology is an absolute prerequisite when AAT is under consideration.1 Plasma phosphorylated tau 217 (p-tau217) is recommended to support the diagnosis of AD pathology.1 Other plasma biomarkers, such as p-tau181 and the Aβ42/Aβ40 ratio, necessitate confirmation with amyloid positron emission tomography (PET) imaging.1

Eligible AAT candidates should have mild cognitive impairment or early dementia primarily based on clinical history.1 Blood pressure control should be achieved before AAT initiation.1 Clinicians should also engage in continuous disease monitoring.1 Patient and caregiver education should be delivered before commencing treatment.1 The use of AAT should be reviewed if progression to moderate dementia is observed.1 Serial magnetic resonance imaging (MRI) scans should be used to monitor the development of amyloid-related imaging abnormalities (ARIA).1 

The successful integration of AAT into regional healthcare infrastructure demands a highly coordinated, multidisciplinary approach.1 The clinical pathway should involve specialists experienced in cognitive impairment, including geriatricians, neurologists, and psychiatrists, who are responsible for candidate selection, baseline evaluations, and the management of behavioral symptoms or severe ARIA complications.1 Nuclear medicine physicians are vital for interpreting amyloid and tau PET imaging and assessing amyloid clearance, while radiologists play a critical role in reviewing baseline scans for lacunar infarcts and meticulously monitoring serial MRIs for ARIA.1 Addressing local logistical challenges, including MRI capacity constraints, the accessibility of advanced plasma biomarkers, and overall cost-effectiveness, will be crucial for the sustainable implementation of these disease-modifying therapies across the healthcare system.1

No.

Consensus statement on AD biomarkers

Evidence quality

Target populations and clinical indications for testing

1

Testing of biomarkers (including plasma, cerebrospinal fluid, or neuroimaging) should only be considered in individuals with clinically relevant cognitive impairment

1

2

Biomarkers may be used in individuals with young-onset dementia (i.e. onset before 65 years of age)

1

3

Biomarkers may be used in individuals with suspected AD and an atypical clinical course (e.g. non-amnestic presentation, rapid or slow progression, or mixed aetiology)

1

4

Biomarkers may be used in individuals with suspected AD and an amnestic presentation

1

5

Biomarkers can be used when AAT is under consideration

1

PET scanning

6

Amyloid PET scanning (using visual interpretation, with or without assistance from standardised uptake value ratio or the Centiloid scale) can be used to confirm AD pathology

1

7

The Centiloid scale is encouraged for comparison of amyloid PET scans performed across different centres and for longitudinal monitoring of treatment response to AATs

1

8

AD plasma biomarkers may be considered as an initial test before proceeding to amyloid PET scanning for confirmation

1

9

Tau PET may aid in the diagnosis of atypical AD and may provide prognostic information in individuals with mild cognitive impairment or those undergoing AATs. At present, it should not be used routinely

2

Other biomarkers

10

Cerebrospinal fluid biomarkers (Aβ42, total tau, phosphorylated tau 181, and ratios including Aβ42/Aβ40, total tau/Aβ42, and phosphorylated tau 181/Aβ42) may be used to confirm AD pathology

1

11

Plasma phosphorylated tau 217 can be used to support the diagnosis of AD pathology. A three-range (two-cutoff) approach, with test sensitivity and specificity of at least 90% in the intended population, is recommended

1

12

Plasma phosphorylated tau 181 may assist in the diagnosis of AD among individuals with cognitive complaints. Confirmation of AD pathology with amyloid PET or cerebrospinal fluid biomarkers is needed

2

13

The plasma Aβ42/Aβ40 ratio may assist in the diagnosis of AD among individuals with cognitive complaints. Confirmation of AD pathology with amyloid PET or cerebrospinal fluid biomarkers is needed. However, robustness remains a major limitation affecting clinical use

1

14

Plasma biomarkers or other diagnostic tests can be used to diagnose AD if they achieve a minimum sensitivity and specificity of at least 90% for the identification of moderate or frequent neuritic plaques at autopsy (gold standard) or approved surrogates (amyloid PET or cerebrospinal fluid biomarkers)

1

Role of professional bodies

15

Given rapid progress in the field of AD biomarkers, local professional bodies should organise updates and share local experience regarding their use.

5

Table 1. Summary of the consensus recommendations on the clinical use of AD biomarkers

AATs: Anti-amyloid therapies; Aβ40: Amyloid beta 40; Aβ42: Amyloid beta 42; AD: Alzheimer's disease; PET: Positron emission tomography

 

 

No.

Consensus statement on AATs

Evidence quality

Patient selection

16

Patients with AD should have either mild cognitive impairment or early dementia. Given the generally lower educational level among the older population, the diagnosis of mild cognitive impairment or mild dementia should be primarily based on clinical history

2

17

The Hong Kong version of the Montreal Cognitive Assessment can be used to support the classification of mild cognitive impairment or mild dementia, with locally validated cutoffs according to age and educational level

2

18

The use of AATs should be reviewed if patients progress to moderate dementia

2

19

Blood pressure should be adequately controlled according to age and co-morbidities before initiation of AATs

4

Monitoring treatment with MRI

20

Patients who are unable to undergo regular MRI (e.g. due to claustrophobia or the presence of MRI-incompatible devices) should not receive AATs

1

21

Serial MRI scans (at least 1.5T, preferably 3.0T) using a standardised protocol and consistent magnetic field strength are recommended during AAT to monitor the development of amyloid-related imaging abnormalities

1

Clinical management and safety monitoring

22

Apolipoprotein E genotyping is recommended before initiation of AATs

2

23

Patients and their relatives should be fully informed of the common non-specific symptoms of amyloid-related imaging abnormalities, including headache, dizziness, confusion, nausea, vision changes, gait disturbance, or seizures. They should be advised to inform the attending physician or emergency department promptly if such symptoms occur, and brain MRI should be arranged as early as possible (if indicated)

1

24

Patients receiving AATs should have an alert in their electronic medical record or be issued a drug card

5

25

A multidisciplinary approach is recommended when administering AATs. This approach involves clinicians experienced in the management of cognitive impairment (e.g. geriatricians, neurologists, psychiatrists, nuclear medicine physicians, and radiologists).

2

26

Infusion reactions, including hypersensitivity and acute symptoms such as fever, chills, or nausea, may occur during administration of anti-amyloid therapies. Protocols should be developed to manage various infusion reactions so that medical staff in wards or day centres can respond promptly and reduce the risk of recurrence

2

 

Table 2. Summary of the consensus recommendations on the clinical use of AAT

AATs: Anti-amyloid therapies; AD: Alzheimer's disease; MRI: Magnetic resonance imaging; T: Tesla

Get access to our exclusive articles.
Related Articles